139 related articles for article (PubMed ID: 26235062)
1. Advanced Assay Monitoring APP-Carboxyl-Terminal Fragments as Markers of APP Processing in Alzheimer Disease Mouse Models.
García-Osta A; Cuadrado-Tejedor M
Methods Mol Biol; 2016; 1303():117-23. PubMed ID: 26235062
[TBL] [Abstract][Full Text] [Related]
2. Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets.
Evin G; Zhu A; Holsinger RM; Masters CL; Li QX
J Neurosci Res; 2003 Nov; 74(3):386-92. PubMed ID: 14598315
[TBL] [Abstract][Full Text] [Related]
3. Phosphorylation of amyloid precursor carboxy-terminal fragments enhances their processing by a gamma-secretase-dependent mechanism.
Vingtdeux V; Hamdane M; Gompel M; Bégard S; Drobecq H; Ghestem A; Grosjean ME; Kostanjevecki V; Grognet P; Vanmechelen E; Buée L; Delacourte A; Sergeant N
Neurobiol Dis; 2005 Nov; 20(2):625-37. PubMed ID: 15936948
[TBL] [Abstract][Full Text] [Related]
4. Proteasome-mediated degradation of the C-terminus of the Alzheimer's disease beta-amyloid protein precursor: effect of C-terminal truncation on production of beta-amyloid protein.
Nunan J; Williamson NA; Hill AF; Sernee MF; Masters CL; Small DH
J Neurosci Res; 2003 Nov; 74(3):378-85. PubMed ID: 14598314
[TBL] [Abstract][Full Text] [Related]
5. Measuring APP carboxy-terminal fragments.
Esposito LA
Methods Mol Biol; 2011; 670():71-84. PubMed ID: 20967584
[TBL] [Abstract][Full Text] [Related]
6. Amyloid-β protein (Aβ) Glu11 is the major β-secretase site of β-site amyloid-β precursor protein-cleaving enzyme 1(BACE1), and shifting the cleavage site to Aβ Asp1 contributes to Alzheimer pathogenesis.
Deng Y; Wang Z; Wang R; Zhang X; Zhang S; Wu Y; Staufenbiel M; Cai F; Song W
Eur J Neurosci; 2013 Jun; 37(12):1962-9. PubMed ID: 23773065
[TBL] [Abstract][Full Text] [Related]
7. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
8. Progressive decrease of amyloid precursor protein carboxy terminal fragments (APP-CTFs), associated with tau pathology stages, in Alzheimer's disease.
Sergeant N; David JP; Champain D; Ghestem A; Wattez A; Delacourte A
J Neurochem; 2002 May; 81(4):663-72. PubMed ID: 12065626
[TBL] [Abstract][Full Text] [Related]
9. Presenilin 1 regulates the processing of beta-amyloid precursor protein C-terminal fragments and the generation of amyloid beta-protein in endoplasmic reticulum and Golgi.
Xia W; Zhang J; Ostaszewski BL; Kimberly WT; Seubert P; Koo EH; Shen J; Selkoe DJ
Biochemistry; 1998 Nov; 37(47):16465-71. PubMed ID: 9843412
[TBL] [Abstract][Full Text] [Related]
10. Retention of the Alzheimer's amyloid precursor fragment C99 in the endoplasmic reticulum prevents formation of amyloid beta-peptide.
Maltese WA; Wilson S; Tan Y; Suomensaari S; Sinha S; Barbour R; McConlogue L
J Biol Chem; 2001 Jun; 276(23):20267-79. PubMed ID: 11278337
[TBL] [Abstract][Full Text] [Related]
11. Does Intraneuronal Accumulation of Carboxyl-terminal Fragments of the Amyloid Precursor Protein Trigger Early Neurotoxicity in Alzheimer's Disease?
Lauritzen I; Pardossi-Piquard R; Bourgeois A; Bécot A; Checler F
Curr Alzheimer Res; 2019; 16(5):453-457. PubMed ID: 30907322
[TBL] [Abstract][Full Text] [Related]
12. Amino-truncated amyloid beta-peptide (Abeta5-40/42) produced from caspase-cleaved amyloid precursor protein is deposited in Alzheimer's disease brain.
Takeda K; Araki W; Akiyama H; Tabira T
FASEB J; 2004 Nov; 18(14):1755-7. PubMed ID: 15364896
[TBL] [Abstract][Full Text] [Related]
13. Amino-terminal modification and tyrosine phosphorylation of [corrected] carboxy-terminal fragments of the amyloid precursor protein in Alzheimer's disease and Down's syndrome brain.
Russo C; Salis S; Dolcini V; Venezia V; Song XH; Teller JK; Schettini G
Neurobiol Dis; 2001 Feb; 8(1):173-80. PubMed ID: 11162251
[TBL] [Abstract][Full Text] [Related]
14. MT5-MMP controls APP and β-CTF/C99 metabolism through proteolytic-dependent and -independent mechanisms relevant for Alzheimer's disease.
García-González L; Paumier JM; Louis L; Pilat D; Bernard A; Stephan D; Jullien N; Checler F; Nivet E; Khrestchatisky M; Baranger K; Rivera S
FASEB J; 2021 Jul; 35(7):e21727. PubMed ID: 34117802
[TBL] [Abstract][Full Text] [Related]
15. Genetic background regulates beta-amyloid precursor protein processing and beta-amyloid deposition in the mouse.
Lehman EJ; Kulnane LS; Gao Y; Petriello MC; Pimpis KM; Younkin L; Dolios G; Wang R; Younkin SG; Lamb BT
Hum Mol Genet; 2003 Nov; 12(22):2949-56. PubMed ID: 14506131
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological characterization of the novel γ-secretase modulator AS2715348, a potential therapy for Alzheimer's disease, in rodents and nonhuman primates.
Mitani Y; Akashiba H; Saita K; Yarimizu J; Uchino H; Okabe M; Asai M; Yamasaki S; Nozawa T; Ishikawa N; Shitaka Y; Ni K; Matsuoka N
Neuropharmacology; 2014 Apr; 79():412-9. PubMed ID: 24373902
[TBL] [Abstract][Full Text] [Related]
17. Selective neutralization of APP-C99 with monoclonal antibodies reduces the production of Alzheimer's Aβ peptides.
Houacine J; Bolmont T; Aeschbach L; Oulad-Abdelghani M; Fraering PC
Neurobiol Aging; 2012 Nov; 33(11):2704-14. PubMed ID: 22317957
[TBL] [Abstract][Full Text] [Related]
18. Homodimerization Protects the Amyloid Precursor Protein C99 Fragment from Cleavage by γ-Secretase.
Winkler E; Julius A; Steiner H; Langosch D
Biochemistry; 2015 Oct; 54(40):6149-52. PubMed ID: 26403946
[TBL] [Abstract][Full Text] [Related]
19. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain.
Güntert A; Döbeli H; Bohrmann B
Neuroscience; 2006 Dec; 143(2):461-75. PubMed ID: 17008022
[TBL] [Abstract][Full Text] [Related]
20. Decrease in brain soluble amyloid precursor protein β (sAPPβ) in Alzheimer's disease cortex.
Wu G; Sankaranarayanan S; Hsieh SH; Simon AJ; Savage MJ
J Neurosci Res; 2011 Jun; 89(6):822-32. PubMed ID: 21433051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
